{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-072603","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.724695+00:00","generated_at":"2026-05-21T05:28:42.593469+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tivic Health Q1 revenue drops 79% to $70K; pursues Entolimod and ncVNS pipeline","bullets":["Revenue fell 79% YoY to $70K; net loss unchanged at $1.5M. Cash $669K vs $2.0M at year-end.","Licensed Phase III TLR5 agonist Entolimod for ARS; began GMP manufacturing validation for BLA.","Briefed White House and FDA on defense applications; secured $25M equity line and $8.4M purchase agreement.","Expanded ncVNS optimization study; regained Nasdaq compliance via 1-for-17 reverse split in March.","Gross margin improved to 72% (vs 50% a year ago) but operating expenses flat at $1.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-072603","json":"https://secwatch.observer/filing/0000950170-25-072603.json","markdown":"https://secwatch.observer/filing/0000950170-25-072603.md","text":"https://secwatch.observer/filing/0000950170-25-072603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/0000950170-25-072603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/tivc-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:28:42.593469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}